Atara Biotherapeutics (ATRA) Short-term Investments (2014 - 2026)

Atara Biotherapeutics (ATRA) has 12 years of Short-term Investments data on file, last reported at $5.4 million in Q2 2025.

• Quarterly Short-term Investments rose 36.25% year-over-year to $5.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $5.4 million (up 36.25% YoY) and the FY2024 annual result came in at $146000.0, down 99.44% from the prior year.
• Short-term Investments advanced to $5.4 million in Q2 2025, from $146000.0 in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $284.1 million in Q1 2021 to a low of $146000.0 in Q1 2023.
• A 5-year average of $54.6 million and a median of $1.3 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2021 — Short-term Investments jumped 125691.75% — and 2023, when it sank 99.93%.
• Tracing ATRA's Short-term Investments over 5 years: stood at $194000.0 in 2021, then soared by 77156.19% to $149.9 million in 2022, then slumped by 82.73% to $25.9 million in 2023, then plunged by 99.44% to $146000.0 in 2024, then surged by 3612.33% to $5.4 million in 2025.
• The last three Short-term Investments figures came in at $5.4 million (Q2 2025), $146000.0 (Q4 2024), and $146000.0 (Q3 2024), per Business Quant data.